Results 11 to 20 of about 1,701 (184)
Modelling the 5‐Year Impact of Twice‐Yearly Injectable Lenacapavir for HIV Pre‐Exposure Prophylaxis in the United States [PDF]
Journal of the International AIDS SocietyIntroduction The impact of pre‐exposure prophylaxis (PrEP) on the US HIV‐1 epidemic has not been fully maximized, potentially due to challenges in uptake, coverage, adherence and consistent use. Following the FDA (Food and Drug Adminstration) approval of
Mia Moore +11 more
doaj +3 more sources
A Scientometric Mapping of Global Lenacapavir and HIV Research: Dynamism, Visualization, and Emerging Patterns [PDF]
International Journal of Preventive MedicineBackground: Lenacapavir, an HIV capsid inhibitor, has shown powerful promise for HIV treatment and prevention purposes. Its new mechanism of action, and other abilities to inhibit viral replication have shown a significant advance, especially in ...
Fran Espinoza-Carhuancho +5 more
doaj +3 more sources
Lenacapavir for HIV Prevention in Africa: Opportunities, Barriers, and Policy Priorities [PDF]
Journal of the International Association of Providers of AIDS CareDespite global progress in HIV prevention, Africa continues to carry a disproportionate share of the epidemic and its related inequalities. Daily oral pre-exposure prophylaxis (PrEP) has been limited by adherence and accessibility challenges. Lenacapavir,
Stanley Chinedu Eneh +13 more
doaj +3 more sources
Emerging concepts in HIV pre-exposure prophylaxis: focus on twice-yearly lenacapavir [PDF]
Drugs in ContextThe persistent global burden of HIV and the need for more flexible, durable prevention strategies have accelerated the development of long-acting pre-exposure prophylaxis (PrEP) options.
Sarah L Anderson
doaj +3 more sources
Baseline Lenacapavir Resistance and Capsid Variability in Bulgaria: A Next-Generation Sequencing Study of Newly Diagnosed HIV-1 Infections [PDF]
PathogensLenacapavir, the first approved HIV-1 capsid inhibitor, is now being introduced for both treatment and pre-exposure prophylaxis, yet the capsid-coding region lies outside the pol fragment examined in routine genotypic resistance testing, and baseline ...
Ivailo Alexiev +14 more
doaj +2 more sources
Drugs, 2022 Abstract Lenacapavir (Sunlenca ® ) is a long-acting capsid inhibitor of human immunodeficiency virus type 1 (HIV-1) being developed by Gilead Sciences Inc. It is available as an oral tablet and injectable solution, with the latter being a slow-release formulation to allow bi-
Julia Paik (6912664)
openaire +3 more sources
Viruses, 2023 Background: With the approval of the HIV-1 capsid inhibitor, lenacapavir, capsid sequencing will be required for managing lenacapavir-experienced individuals with detectable viremia.
Kaiming Tao +6 more
doaj +2 more sources
Frontiers in Microbiology, 2022 The HIV p24 capsid protein has an essential, structural, and functional role in the viral replication cycle, being an interesting target for vaccine design, diagnostic tests, and new antiretroviral drugs (ARVs).
Paloma Troyano-Hernáez +2 more
doaj +2 more sources
Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
Case Reports in Infectious Diseases, 2023 We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects.
Ferdinand Bigirimana +6 more
doaj +2 more sources
Lenacapavir’s Success: Revitalizing Antiviral Drug Discovery
VirulenceDavid Jesse Sanchez, Daniel Miranda
exaly +5 more sources